Sebia, a world leader in multiple myeloma diagnostics and monitoring, has introduced M-inSight its serum-based Minimal Residual Disease (MRD) test for monitoring in multiple myeloma. M-inSight is a Laboratory Developed Test (LDT) being offered by Corgenix, part of the Sebia Group.
ScreenIn3D reports on how their proprietary lab-on-a-chip technology is enabling cancer researchers to miniaturize their testing of biopsy tissue samples across a wide range of modalities and to test both single and combination drug therapies on live tissue samples.
Polpharma Biologics, an international biotech company focused on developing and manufacturing biosimilars, has received approval from the European Commission for Tyruko (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe. Tyruko was developed by Polpharma Biologics and will be commercialized by its collaboration partner Sandoz.
Revvity has expanded its imaging portfolio with the introduction of three new imaging systems – the IVIS platform, the Quantum GX3 microCT, and the Vega ultrasound system.
Shimadzu has released the AIMsight infrared microscope. AIMsight builds on the high sensitivity of Shimadzu’s well-known AIM-9000 to offer an improved operational experience through greater automation. AIMsight is intended for industrial applications, such as drug manufacturing.
The COMBO-ONE Viscometer/DRI detector from TESTA Analytical sets a new standard for demanding GPC/SEC applications, such as those focused on investigating the structure and branching of polymers.
INTEGRA Biosciences has launched MIRO CANVAS, a compact digital microfluidics platform for fully automated next generation sequencing (NGS) sample preparation. The revolutionary system significantly simplifies NGS workflows for more walk-away time and higher lab productivity.
The Micro Flow Meter from Biotech Fluidics is a new device designed to continuously monitor ultra-low fluidic flows in real-time.
The pathology laboratory has been fitted out with industry gold standard equipment including ground-breaking technology in the diagnosis of cancer conditions which will enable a far greater volume of accurate tests to be processed, around the clock, seven days a week.
Investment to expand cell line development capabilities and accelerate customer workflows, as part of its diverse and tailored antibody solutions
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
